

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of China NT Pharma Group Company Limited (the “**Company**”) dated 28 April 2025 and the clarification announcement dated 29 April 2025 (the “**Announcements**”) in relation to the acquisition of 100% of the issued shares in the Target Companies involving the issue of consideration Shares under specific mandate. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, a circular containing, among others, details of the Sale and Purchase Agreement and the transactions contemplated thereunder and other information as required under the Listing Rules together with the notice convening the EGM and the proxy form is expected to be despatched to the Shareholders on or before 30 June 2025 (the “**Circular**”). As additional time is required for the Company to finalise certain information in the Circular, it is expected that the date of despatch of the Circular will be postponed to a date on or before 31 October 2025.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 30 June 2025

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Director is Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.